SCHEDULE 13G/A: Nantahala Capital Partners Discloses 1.9% Stake in Senti Biosciences

Nantahala Capital Partners Limited Partnership has filed an amended Schedule 13G, reporting a beneficial ownership of 1.9% in Senti Biosciences, Inc. as of March 31, 2025.

Summary

• Nantahala Capital Partners Limited Partnership (Nantahala) has filed an Amendment No. 1 to Schedule 13G regarding its ownership in Senti Biosciences, Inc.
• As of March 31, 2025, Nantahala beneficially owns 502,500 shares of Senti Biosciences' common stock.
• This ownership represents 1.9% of the total outstanding shares of Senti Biosciences, based on 26,004,266 shares outstanding.
• The reported beneficial ownership includes 301,500 shares that Nantahala may acquire within sixty days through the exercise of warrants.
• Nantahala holds shared voting power and shared dispositive power over all 502,500 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of Senti Biosciences.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Senti Biosciences or Nantahala Capital Partners regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a passive investment stake by Nantahala Capital Partners in Senti Biosciences, a biotechnology company. Such filings are standard disclosures in the investment community, providing transparency on significant ownership positions. While not indicative of a strategic shift, it signals continued interest from an institutional investor in the biotech sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake by an institutional investor, Nantahala Capital Partners. This indicates continued institutional interest in Senti Biosciences.

Key Dates

Keywords

Senti Biosciences, Nantahala Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment, Biotechnology